What investors actually buy when they buy “longevity” — and what happens next.
A category-aware reading of $1.73B+ deployed across the longevity sector in 2025, plus seven non-consensus forecasts and twelve named-deal tracked predictions for the 24 months ahead. By Tetiana Honcharenko & Aleksey Konstantinov · The Blue · Edition v0.1, May 2026.
Three findings
- Three deals took three-quarters of 2025 capital. Pure-play healthspan companies raised ~$1.73B across 25 qualifying deals — the top three captured the majority.
- “AI platform” framing is load-bearing — and often misread. All three largest 2025 deals lead with AI / data / platform language; underneath sit very different evidence ladders and capital horizons.
- Cellular reprogramming is the concentration inside the concentration. ~$4.7B — 62% of all longevity funding over four years — rests on structurally the same wager, placed four times. One human-trial failure re-prices the others.
What’s inside
- A seven-category map of the longevity market — how each category earns, fails, and is valued.
- Seven explicit, falsifiable 24-month forecasts the market is not yet pricing.
- Twelve named-deal tracked predictions with timing windows and resolution criteria.
- Embedded case write-ups of six deals plus three previously published adverse cases.
Written for the family-office CIO, longevity-specialist allocator, or strategic corporate-venture partner who wants to know which test to apply before the next check.
Get the report
Register and we’ll email your copy — your download will also appear below.
Not investment advice. Not a solicitation. The Blue is not a licensed investment firm.